Latest Breaking News On - Centro integral oncol - Page 1 : comparemela.com

Alkermes plc: Alkermes Presents New Nemvaleukin Alfa Monotherapy Data at the American Society of Clinical Oncology Genitourinary Cancers Symposium

- Data From ARTISTRY-1 Clinical Trial Highlight Single-Agent, Anti-Tumor Activity of Nemvaleukin in Patients With Renal Cell Carcinoma - DUBLIN, Feb. 17, 2022 /PRNewswire/ Alkermes

United statesEmiliano calvoCraig hopkinsonSandy coombsSourojit bhowmickAmerican society of clinical oncologyResearch development at alkermesMerck sharp dohme corpExchange commissionNemvaleukin clinical development programMerck co incClinical researchTrial highlight single agentAnti tumor activityPatients with renal cell carcinomaAmerican society

Alkermes Presents New Nemvaleukin Alfa Monotherapy Data at the American Society of Clinical Oncology Genitourinary Cancers Symposium

/PRNewswire/ Alkermes plc (Nasdaq: ALKS) today presented new data from the ongoing phase 1/2 ARTISTRY-1 clinical trial for nemvaleukin alfa (nemvaleukin),.

United statesEmiliano calvoCraig hopkinsonSandy coombsSourojit bhowmickAmerican society of clinical oncologyResearch development at alkermesMerck sharp dohme corpExchange commissionNemvaleukin clinical development programMerck co incClinical researchAmerican societyClinical oncologyCancers symposiumChief medical officer

Alkermes plc Reports Second Quarter 2021 Financial Results

Alkermes plc Reports Second Quarter 2021 Financial Results
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesKatie joyceEmily peterson alvaIain brownValentina boniOmid hamidSandy coombsCompany updatesAmerican society of clinical oncologyBiogen incExchange commissionResearch instituteAlkermes incAlkermes pharma irelandSecond quarter revenuesGrowth year over

Alkermes Presents New Data on Nemvaleukin Alfa at 2021 American Society of Clinical Oncology Annual Meeting

/PRNewswire/ Alkermes plc (Nasdaq: ALKS) today announced new data from its ARTISTRY clinical development program for nemvaleukin alfa (nemvaleukin),.

United statesValentina boniOmid hamidCraig hopkinsonSandy coombsSourojit bhowmickAmerican society of clinical oncologyResearch development at alkermesClinical development programMerck sharp dohme corpMerck co incExchange commissionResearch instituteClinical oncologyAnnual meetingLead investigator

Alkermes to Host Webcast With Expert Oncologist Panel to Discuss Data on Nemvaleukin Alfa Presented at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

- Webcast to be Held at 4:00 p.m. ET on Friday, June 4 - DUBLIN, May 28, 2021 /PRNewswire/ Alkermes plc (Nasdaq: ALKS) today announced that it will host a webcast and conference call

United statesValentina boniOmid hamidSandy coombsSourojit bhowmickAmerican society of clinical oncologyClinical development programMerck sharp dohme corpMerck co incResearch instituteClinical oncologyAnnual meetingMedical oncologistPrincipal investigatorCentro integral oncolClara campal